New: NCI-funded clinical trial search
Mednet Logo
CommunityPulmonology

Pulmonology

Physician discussions on respiratory conditions, critical care, interstitial lung disease, and pulmonary procedures.

Recent Discussions

Do you recommend IV sodium bicarbonate for patients with rhabdomyolysis and AKI without metabolic alkalosis or hypocalcemia?

5 Answers

Mednet MemberInvited Expert
Nephrology · The University of Texas Health Science Center at San Antonio

The primary goal of IV fluids and urine alkalinization in patients with rhabdomyolysis is to prevent AKI, not to treat established AKI. The most important factor in preventing AKI is early and vigorous fluid administration (aiming to achieve a brisk diuresis of 200-400 ml/hr), while the choice of IV...

Do you check blood eosinophil counts in patients with COPD exacerbations to help guide therapy decisions?

2
1 Answers

Mednet MemberInvited Expert
Pulmonology · UCSD

Yes, I check blood eosinophils in my COPD patients to better understand whether T2 (allergic) inflammation might be contributing, and thus give insight as to which biologic options may be the best for long-term care. For an eosinophil-high (≥300 cells/uL) patient who exacerbates, triple inhaled ther...

How do you manage a hospitalized patient with OSA and likely OHS who refuses CPAP or BIPAP, including at discharge?

2 Answers

Mednet MemberInvited Expert
Hospital Medicine · Emory University Hospital

For discharge planning, I would involve Pulmonology or Sleep Medicine early, particularly in patients with documented hypercapnia or recent acute-on-chronic respiratory failure. The American Thoracic Society recommends discharge with noninvasive ventilation for patients hospitalized with respiratory...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

In patients treated with infliximab, do rates of immunogenicity vary based on underlying disease (RA, IBD, sarcoidosis, etc) and/or baseline disease activity?

2
1 Answers

Mednet MemberInvited Expert
Rheumatology · Harvard Medical School

Yes, rates of infliximab immunogenicity appear to vary based on underlying disease, with evidence showing higher rates for RA than IBD and spondyloarthritis, and tend to increase with higher baseline disease activity. Most patients tend to develop anti-drug antibodies within the first year, but this...

In light of recent measles outbreaks in the US, would you recommend an MMR booster for immunocompetent patients born before 1957?

5
6 Answers

Mednet MemberInvited Expert
Infectious Disease · Perelman School of Medicine at the University of Pennsylvania

I would not recommend a measles vaccine for a person born before 1957. This year has been chosen because people before born before 1957 have a very very high likelihood of having had measles because virtually all children got this highly contagious disease. On the other hand, there is no harm to get...

How are you using liquid biopsy in the routine management of your patients with metastatic NSCLC?

5
2 Answers

Mednet MemberInvited Expert
Medical Oncology · Albert Einstein College of Medicine at Montefiore Medical Center

The dramatic improvement in the prognosis of metastatic NSCLC patients harboring targetable oncogenic genetic alterations with highly effective therapy has underscored the need for tumor molecular profiling. There have been numerous studies in the past decade assessing the performance of ctDNA (here...

What clinical features push you to add dupilumab instead of escalating ICS dose in a patient with biomarker-high asthma and recurrent exacerbations?

3 Answers

Mednet MemberInvited Expert
Allergy & Immunology · University of Mississippi School of Medicine

The Phase 3 QUEST study addressed this question and found that adding dupilumab to medium-dose ICS/LABA provided significantly better control than placebo plus high-dose ICS. However, this study did not look at actual dose escalation of the ICS prior to instituting the biologic. They also found no s...

Would you reserve dupilumab for postsurgical recurrence or offer it upfront for high-burden disease in a patient with allergic fungal rhinosinusitis?

1 Answers

Mednet MemberInvited Expert
Allergy & Immunology · University of Mississippi School of Medicine

This is a practical, salient question that has (at least as of yet) no definitive answer. Given the typical morbidity of AFRS patients with significant polyp burden and the not infrequent need for systemic steroid bursts to manage extreme symptom recurrence, it is not unreasonable to consider starti...

How do you approach caring for patients admitted with decompensated CHF, but who also exhibit hypotension and do not have overt signs of hypervolemia on exam?

5
5 Answers

Mednet MemberInvited Expert
Cardiology · NYU Langone Health

This is a case where you might be concerned about the patient sliding into cardiogenic shock. Remember that in the context of chronic heart failure, cardiogenic shock tends to present more insidiously because these patients are typically compensated at low or borderline low cardiac output (Abraham e...

When do you consider starting a bicarbonate drip for hospitalized patients?

2 Answers

Mednet MemberInvited Expert
Hospital Medicine · Jefferson University Physicians

In general, it’s best to follow the serum pH and not the bicarbonate, as there can be respiratory compensationYou should start to worry when the serum bicarbonate is in the range of 10 to 13. Strongest case for treating: pH ≤7.10 with AKI stage 2–3, especially in shock or sepsis. Weaker case: pH bet...